KESHAV
Informasi obat, indikasi, dosis, dan keamanan yang terkait dengan produk yang tersedia saat ini.
歌礼制药-B(01672)向美国FDA递交两项治疗肥胖症的IND申请：多肽胰淀素受体激动剂月注射剂ASC36以及ASC36联合多肽GLP-1R/GIPR激动剂ASC35的ASC36_35复方月注射剂 凤凰网
恒瑞医药披露口服小分子GLP-1受体激动剂HRS-7535第二项中国关键Ⅲ期Type 2 diabetes研究（OUTSTAND-2）积极顶线结果 ByDrug
Mitotane Market Growth and Status Explored In A New Research openPR.com
FDA Approval of Acalabrutinib Plus Venetoclax Brings an All-Oral, Fixed-Duration Option to Frontline CLL Care OncLive
Lumakras (Sotorasib) in combination with Vectibix (Panitumumab) FDA Approved for Metastatic Colorectal Cancer with KRAS G12C Mutation news.cancerconnect.com
Dabrafenib plus trametinib in BRAFV600E -mutated rare cancers: the phase 2 ROAR trial Nature
